Results 31 to 40 of about 2,780 (85)

FEELINGS, RECEPTION AND HUMANIZATION IN PALLIATIVE CARE TO CHILDREN WITH LEUKEMIA

open access: yesRevista de Pesquisa Cuidado é Fundamental Online, 2013
Objetivo: Compreender a visão da equipe multidisciplinar perante a criança portadora de leucemia, em cuidado paliativo. Métodos: O presente estudo é de abordagem qualitativa, delineado pelo método de estudo de caso.
Mayara Rosário Soares   +5 more
doaj   +4 more sources

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, Volume 20, Issue 4, Page 947-961, April 2026.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients

open access: yesHemaSphere, Volume 10, Issue 4, April 2026.
Abstract Neurotoxicity is a common and potentially life‐threatening complication after chimeric antigen receptor T‐cell therapy (CART) for pediatric B‐cell acute lymphoblastic leukemia (B‐ALL). The only consistently demonstrated clinical risk factor for severe neurotoxicity in prior studies is high, preinfusion bone marrow disease burden (DB).
Caroline Diorio   +18 more
wiley   +1 more source

Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long‐term results from FIL‐FLAZ12 Phase III trial

open access: yes
HemaSphere, Volume 10, Issue 8, August 2026.
Rita Tavarozzi   +46 more
wiley   +1 more source

Evidence and Equity Gaps in Clinical Care of Chronic Lymphocytic Leukaemia in Portugal: A Real‐World, Multicentre, Cohort Study

open access: yeseJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Objectives Targeted therapies have markedly improved outcomes in chronic lymphocytic leukaemia (CLL), particularly among patients with TP53 alterations and unmutated IGHV. However, real‐world studies report persistent inequalities in access to optimal care.
Susana Esteves   +7 more
wiley   +1 more source

Shared Decision‐Making in Treatment Selection in Multiple Myeloma in Spain: The PRISMMA Study

open access: yesEuropean Journal of Haematology, Volume 116, Issue 2, Page 185-194, February 2026.
ABSTRACT Introduction Perceptions and experiences of shared decision‐making between patients and physicians in multiple myeloma (MM) care are not fully understood. A survey study was conducted to explore these perspectives in Spain. Methods Two anonymous online surveys, one for haematologists and one for MM patients, were developed.
Valentín Cabañas   +5 more
wiley   +1 more source

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T‐Cell Immunotherapy for B‐Cell Malignancies: A Case Series

open access: yes
Hematological Oncology, Volume 44, Issue 4, July 2026.
Gianluca Cavallaro   +12 more
wiley   +1 more source

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities

open access: yesInternational Journal of Cancer, Volume 158, Issue 2, Page 423-432, 15 January 2026.
Abstract In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly.
Subhasree Kumar   +2 more
wiley   +1 more source

DIAGNÓSTICOS E INTERVENÇÕES DE ENFERMAGEM PARA PACIENTE COM LEUCEMIA LINFOCÍTICA AGUDA: ESTUDO DE CASO CLÍNICO

open access: yesRevista de Ciências da Saúde Nova Esperança, 2004
As Leucemias Linfocíticas Agudas (LLA) encontram-se na classificação dos cânceres hematopoiéticos e caracterizam-se pela produção excessiva de linfócitos malignos.
Nailze Figueiredo Souza de Oliveira   +3 more
doaj   +1 more source

Quality of Life and Needs of Patients Undergoing CAR‐T Cell Therapy: The Patients’ Perspective

open access: yesEuropean Journal of Cancer Care, Volume 2026, Issue 1, 2026.
Background Despite the strong emphasis in recent scientific literature on the pharmacological features of CAR‐T cells, patients’ quality of life (QoL) and needs, by contrast, have received little attention. Aim This study aims to investigate patients’ perspectives on their QoL and needs in a referral centre for CAR‐T cell treatment in Italy.
S. Alfieri   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy